You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK2

Showing 1 - 25 of 479
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Arteriovenous Malformations Trial (Trametinib tablet)

Not yet recruiting
  • Arteriovenous Malformations
  • Trametinib tablet
  • (no location specified)
Oct 17, 2023

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma Trial in Leiden (Encorafenib + Binimetinib)

Recruiting
  • Melanoma Stage III
  • In-Transit Metastasis of Cutaneous Melanoma
  • Encorafenib + Binimetinib
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Mar 2, 2023

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

Active, not recruiting
  • Gastrointestinal Cancer
  • New York, New York
  • +1 more
Nov 29, 2022

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer Trial in United States (Mirdametinib, Fulvestrant)

Recruiting
  • Breast Cancer
  • +6 more
  • Middletown, New Jersey
  • +3 more
Dec 28, 2021

Prostate Cancer Trial in Los Angeles (degarelix, enzalutamide, trametinib)

Active, not recruiting
  • Prostate Cancer
  • Los Angeles, California
    University of California, Los Angeles
Aug 25, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)

Not yet recruiting
  • Endometrioid Cancer
  • +3 more
  • VS-6766 + defactinib
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Aug 19, 2022

Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

Active, not recruiting
  • Tumor Skin
  • +2 more
  • OBX-115
  • Orlando, Florida
  • +1 more
Sep 28, 2023

Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma Trial in Memphis (Mirdametinib)

Recruiting
  • Low-Grade Glioma
  • +2 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 24, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston

Active, not recruiting
  • Metastatic Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +6 more
  • Boston, Massachusetts
  • +1 more
Nov 8, 2022

Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

Recruiting
  • Advanced Solid Tumor (Phase 1)
  • +4 more
  • Duarte, California
  • +4 more
Feb 2, 2023

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

Metastatic Uveal Melanoma Trial in Philadelphia (Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766)

Recruiting
  • Metastatic Uveal Melanoma
  • Defactinib Hydrochloride
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 23, 2023

Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Tumor Trial in Buffalo (Binimetinib, Palbociclib, Therapeutic

Recruiting
  • Colorectal Carcinoma
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
May 11, 2022

BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

Recruiting
  • BRAF NP_004324.2:p.V600E
  • +2 more
  • Duarte, California
  • +1 more
Jan 19, 2023

EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

Recruiting
  • EGFR NP_005219.2:p.S492R
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Binimetinib Oral Tablet

Not yet recruiting
  • Adamantinous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Binimetinib Oral Tablet [Mektovi]
  • Aurora, Colorado
  • +17 more
Nov 28, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • (no location specified)
Nov 8, 2022

Malignant Solid Tumor, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma Trial (Binimetinib, Biopsy, Biospecimen

Not yet recruiting
  • Malignant Solid Neoplasm
  • +4 more
  • (no location specified)
Nov 8, 2022

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022